evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

34 questions · 34 findings · 22 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 2.9%GRADE not reported 2 · 5.9%Very low 8 · 23.5%Low 12 · 35.3%Moderate 8 · 23.5%High 3 · 8.8%

Azithromycin vs placebo or usual care

All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…

Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).

1 finding from 1 review

Azithromycin vs placebo or usual care

All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (low certainty).

1 finding from 1 review

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

All‐cause mortality (by day 28) · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in all‐cause mortality (by day 28) compared with saline placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care

All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

All‐cause mortality at up to day 28 · outpatients withmild disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with placebo or standard care alone (very low certainty).

1 finding from 1 review

Remdesivir and standard care vs placebo or usual care

All‐cause mortality at up to day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Remdesivir and standard care vs placebo or usual care

All‐cause mortality at up to day 281 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review